JPS60501540A - 細胞外マトリクスの体移植片並びに該移植片の製造及び使用のための手段及び方法 - Google Patents
細胞外マトリクスの体移植片並びに該移植片の製造及び使用のための手段及び方法Info
- Publication number
- JPS60501540A JPS60501540A JP59502264A JP50226484A JPS60501540A JP S60501540 A JPS60501540 A JP S60501540A JP 59502264 A JP59502264 A JP 59502264A JP 50226484 A JP50226484 A JP 50226484A JP S60501540 A JPS60501540 A JP S60501540A
- Authority
- JP
- Japan
- Prior art keywords
- detergent
- graft
- tissue
- extracellular matrix
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 69
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims description 25
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims description 25
- 210000002744 extracellular matrix Anatomy 0.000 title claims description 25
- 239000007943 implant Substances 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000003599 detergent Substances 0.000 claims description 104
- 210000001519 tissue Anatomy 0.000 claims description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 19
- 230000002792 vascular Effects 0.000 claims description 18
- 102000008186 Collagen Human genes 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 claims description 16
- 229920001436 collagen Polymers 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 13
- 210000000170 cell membrane Anatomy 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 11
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000001086 cytosolic effect Effects 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 4
- 210000000633 nuclear envelope Anatomy 0.000 claims description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 210000004940 nucleus Anatomy 0.000 claims description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 2
- 235000014676 Phragmites communis Nutrition 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 238000010382 chemical cross-linking Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 50
- 239000000463 material Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 210000003017 ductus arteriosus Anatomy 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 10
- 210000001715 carotid artery Anatomy 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 210000000515 tooth Anatomy 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 238000011888 autopsy Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 210000003954 umbilical cord Anatomy 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 239000000834 fixative Substances 0.000 description 6
- 210000003041 ligament Anatomy 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 210000002469 basement membrane Anatomy 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 230000003872 anastomosis Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940009976 deoxycholate Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 206010006803 Burns third degree Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZUBJEHHGZYTRPH-KTKRTIGZSA-N [(z)-octadec-9-enyl] hydrogen sulfate Chemical class CCCCCCCC\C=C/CCCCCCCCOS(O)(=O)=O ZUBJEHHGZYTRPH-KTKRTIGZSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 210000002747 omentum Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 231100000732 tissue residue Toxicity 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000001270 Allium sibiricum Nutrition 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000007064 DNA hydrolysis Effects 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000238558 Eucarida Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241001529596 Pontinus kuhlii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000208474 Protea Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 208000008010 Tooth Avulsion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VXLCKSFMONBCLQ-UHFFFAOYSA-N [Na]CC[Na] Chemical group [Na]CC[Na] VXLCKSFMONBCLQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960001162 dihydrostreptomycin sulfate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical compound [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- KKXWPVVBVWBKBL-UHFFFAOYSA-N n,n-diethylethanamine;dodecyl hydrogen sulfate Chemical compound CC[NH+](CC)CC.CCCCCCCCCCCCOS([O-])(=O)=O KKXWPVVBVWBKBL-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- DFCXLPXOMCCXKM-UHFFFAOYSA-N phenylmethanesulfonic acid;hydrofluoride Chemical compound F.OS(=O)(=O)CC1=CC=CC=C1 DFCXLPXOMCCXKM-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50320383A | 1983-06-10 | 1983-06-10 | |
| US503,203 | 1983-06-10 | ||
| US582,504 | 1984-02-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60501540A true JPS60501540A (ja) | 1985-09-19 |
| JPH0550295B2 JPH0550295B2 (de) | 1993-07-28 |
Family
ID=24001137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59502264A Granted JPS60501540A (ja) | 1983-06-10 | 1984-05-24 | 細胞外マトリクスの体移植片並びに該移植片の製造及び使用のための手段及び方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS60501540A (de) |
| ZA (1) | ZA843751B (de) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0829160B2 (ja) * | 1985-03-01 | 1996-03-27 | アンステイテユ・ナシオナル・ドウ・ラ・サンテ・エ・ドウ・ラ・ルシエルシユ・メデイカル | エラスチンをベ−スとする生成物、その製造方法並びに特に生体用補綴物質及び人工支持体としての生物学的適用 |
| JP2013507164A (ja) * | 2009-10-07 | 2013-03-04 | ケレシス・イーエイチエフ | 創傷ケア及び／又は他の組織治癒適用のための骨格材料 |
| WO2014181767A1 (ja) | 2013-05-07 | 2014-11-13 | 国立大学法人 東京医科歯科大学 | 粒子状脱細胞化組織の製造方法 |
| JP2015160040A (ja) * | 2014-02-28 | 2015-09-07 | 株式会社Adeka | 脱細胞組織の製造方法 |
| KR20170122178A (ko) | 2015-02-27 | 2017-11-03 | 가부시키가이샤 아데카 | 탈세포화 조직 |
| KR20170128385A (ko) | 2015-03-12 | 2017-11-22 | 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 탈세포화 조직을 사용한 유착 방지재 및 대용 생체막 |
| WO2018221402A1 (ja) | 2017-05-30 | 2018-12-06 | 哲哉 樋上 | 移植用脱細胞化材料の製造方法及び当該材料を含む生体適合性材料からなる移植片組成物 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3649163A (en) * | 1968-03-25 | 1972-03-14 | American Cyanamid Co | Method for removing noncollagenous matter from mammalian gut |
| US3777599A (en) * | 1971-08-23 | 1973-12-11 | Burn Treatment Skin Bank Inc | Process for producing split-thickness animal skin for protecting flayed human tissue |
| JPS51124094A (en) * | 1975-04-10 | 1976-10-29 | Yeda Res & Dev | Method of providing explant |
| JPS521011A (en) * | 1975-01-23 | 1977-01-06 | Dardik Irving I | Nonnantigenic * nonnthrombogenic * dyessresistant transplant from umbilkal cord and its preparation and usage |
| US4239492A (en) * | 1979-06-14 | 1980-12-16 | Beisang Arthur A | Method of preparing vascular grafts of human and other umbilical cord origins for tissue ingrowth |
| US4352887A (en) * | 1979-10-29 | 1982-10-05 | Albert Einstein College Of Medicine Of Yeshiva University | Method and article for culturing differentiated cells |
| JPS57190555A (en) * | 1981-04-30 | 1982-11-24 | Extracorporeal Medical | Anti-carcarous tissue for transplantation |
-
1984
- 1984-05-17 ZA ZA843751A patent/ZA843751B/xx unknown
- 1984-05-24 JP JP59502264A patent/JPS60501540A/ja active Granted
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3649163A (en) * | 1968-03-25 | 1972-03-14 | American Cyanamid Co | Method for removing noncollagenous matter from mammalian gut |
| US3777599A (en) * | 1971-08-23 | 1973-12-11 | Burn Treatment Skin Bank Inc | Process for producing split-thickness animal skin for protecting flayed human tissue |
| JPS521011A (en) * | 1975-01-23 | 1977-01-06 | Dardik Irving I | Nonnantigenic * nonnthrombogenic * dyessresistant transplant from umbilkal cord and its preparation and usage |
| JPS51124094A (en) * | 1975-04-10 | 1976-10-29 | Yeda Res & Dev | Method of providing explant |
| US4239492A (en) * | 1979-06-14 | 1980-12-16 | Beisang Arthur A | Method of preparing vascular grafts of human and other umbilical cord origins for tissue ingrowth |
| US4352887A (en) * | 1979-10-29 | 1982-10-05 | Albert Einstein College Of Medicine Of Yeshiva University | Method and article for culturing differentiated cells |
| JPS57190555A (en) * | 1981-04-30 | 1982-11-24 | Extracorporeal Medical | Anti-carcarous tissue for transplantation |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0829160B2 (ja) * | 1985-03-01 | 1996-03-27 | アンステイテユ・ナシオナル・ドウ・ラ・サンテ・エ・ドウ・ラ・ルシエルシユ・メデイカル | エラスチンをベ−スとする生成物、その製造方法並びに特に生体用補綴物質及び人工支持体としての生物学的適用 |
| JP2013507164A (ja) * | 2009-10-07 | 2013-03-04 | ケレシス・イーエイチエフ | 創傷ケア及び／又は他の組織治癒適用のための骨格材料 |
| EP3556406A1 (de) | 2013-05-07 | 2019-10-23 | National University Corporation Tokyo Medical and Dental University | Verfahren zur herstellung eines partikelförmigen dezellularisierten gewebes |
| WO2014181767A1 (ja) | 2013-05-07 | 2014-11-13 | 国立大学法人 東京医科歯科大学 | 粒子状脱細胞化組織の製造方法 |
| KR20160005712A (ko) | 2013-05-07 | 2016-01-15 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 입자상 탈세포화 조직의 제조방법 |
| JP2015160040A (ja) * | 2014-02-28 | 2015-09-07 | 株式会社Adeka | 脱細胞組織の製造方法 |
| KR20170122178A (ko) | 2015-02-27 | 2017-11-03 | 가부시키가이샤 아데카 | 탈세포화 조직 |
| EP3782629A1 (de) | 2015-02-27 | 2021-02-24 | Adeka Corporation | Dezellularisiertes gewebe |
| KR20170128385A (ko) | 2015-03-12 | 2017-11-22 | 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 탈세포화 조직을 사용한 유착 방지재 및 대용 생체막 |
| US11033661B2 (en) | 2015-03-12 | 2021-06-15 | Adeka Corporation | Anti-adhesion material and substitute biomembrane using decellularized tissue |
| KR20200016226A (ko) | 2017-05-30 | 2020-02-14 | 가부시키가이샤 아데카 | 이식용 탈세포화 재료의 제조 방법 및 당해 재료를 포함하는 생체 적합성 재료로 이루어지는 이식편 조성물 |
| WO2018221402A1 (ja) | 2017-05-30 | 2018-12-06 | 哲哉 樋上 | 移植用脱細胞化材料の製造方法及び当該材料を含む生体適合性材料からなる移植片組成物 |
| KR20250007698A (ko) | 2017-05-30 | 2025-01-14 | 가부시키가이샤 아데카 | 이식용 탈세포화 재료의 제조 방법 및 당해 재료를 포함하는 생체 적합성 재료로 이루어지는 이식편 조성물 |
| US12403219B2 (en) | 2017-05-30 | 2025-09-02 | Adeka Corporation | Method for producing decellularized material for transplantation and graft composition consisting of biocompatible material including said material |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0550295B2 (de) | 1993-07-28 |
| ZA843751B (en) | 1984-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4801299A (en) | Body implants of extracellular matrix and means and methods of making and using such implants | |
| JP5142437B2 (ja) | 組織移植片 | |
| ES2231984T3 (es) | Limpieza quimica de material biologico. | |
| US9936688B2 (en) | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced | |
| JP6480911B2 (ja) | 組織移植片の脱細胞化方法 | |
| JP2539934B2 (ja) | 移植組織 | |
| CN100333702C (zh) | 一种无细胞的异种角膜基质及制备方法和用途 | |
| JPH09512463A (ja) | 天然内皮下基質を利用した改善された血液接触表面並びにその製造及び利用方法 | |
| JPH09502379A (ja) | 天然組織の改良された架橋 | |
| TW201639585A (zh) | 使用去細胞化組織之沾黏防止材及代用生體膜 | |
| WO2017175870A1 (ja) | 肝切除を受けた肝臓の組織再構築用移植材、その製造方法、及び肝切除を受けた肝臓の再構築方法 | |
| TWI749233B (zh) | 移植用去細胞化材料之製造方法以及包含該材料之生體適合性材料而成之移植片組成物 | |
| RU2353397C2 (ru) | Биорассасываемая коллагеновая матрица, способ ее получения и применение | |
| JPH0550295B2 (de) | ||
| JP5610268B2 (ja) | 高張電解質溶液による生体組織の脱細胞化処理方法 | |
| Strömberg et al. | An experimental study of autologous digital tendon transplants in the horse | |
| CN117085183B (zh) | 一种原位固化、无缝合移植材料及其制备方法和应用 | |
| JP2004167236A (ja) | 気管移植片の調製方法、気管移植片、凍結乾燥気管マトリックス片および細胞の播種方法 | |
| US7011829B2 (en) | Tissue filler | |
| Purohit | Sameer Shrivastava, Sonal Saxena, Swapan Kumar Maiti, and Karam Pal Singh | |
| KR100342384B1 (ko) | 자가점막이식 기도 인공 삽입물 | |
| Purohit et al. | Tissue Scaffolds Derived from Buffalo Skin and Clinical Applications | |
| Sokol et al. | Prospects for application of bovine pericardial scaffold for cardial surgery | |
| CN117205371A (zh) | 脱细胞生物材料及其制备方法、应用 | |
| KR101709008B1 (ko) | 생체 적합성이 증진된 진피대체물의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |